ArticleBone marrow transplantation2018

Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival.

Marietta Nygaard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.